Carlat Psychiatry News | Stimulant Fraud • Oral Ketamine • E-Cigarettes • Benzo Tapering • CBD
💡Subscribe to our newsletter: https://www.thecarlatreport.com/products
➡️Check out our website: https://www.thecarlatreport.com/
================
Follow Carlat:
🔴SUBSCRIBE ► / @thecarlatreport
➡️Twitter: / CarlatPsych
================
0:00 – Intro
0:29 DOJ Charges Telehealth Executives
1:55 Oral Extended Release Ketamine
3:29 MDMA Trials Suspended
04:43 Liquid Clonidine and Liquid Lithium
5:46 Benzodiazepine Tapering Guidelines
8:01 Antidepressants in Bipolar Disorder
10:52 Vaping Trials and Smoking Cessation
12:54 Brexpiprazole & Sertraline For PTSD
14:15 CBD Oil for Anxiety
#MentalHealthNews #psychiatry #psychiatricmedications #psychnews #psychiatrynews #psychopharmacology #pmhnp #psychnp
================
In this episode, we explore nine groundbreaking stories in mental health and psychiatric medicine, covering everything from healthcare fraud to the latest advancements in drug trials. First, we dive into the recent charges brought by the US Department of Justice against executives at Done, a California-based telehealth company, for alleged healthcare fraud. Done is accused of prescribing over 40 million Adderall pills to patients without proper evaluation, raising concerns about the balance between increasing mental healthcare access and responsible prescribing practices.
Then, we look at the ongoing nationwide stimulant shortage affecting ADHD patients, with more than 30,000 to 50,000 people possibly impacted. This disruption comes at a critical time, as new trials are being conducted on oral, at-home ketamine, showing both promise and challenges in treating treatment-resistant depression. We discuss how the FDA will need to grapple with the broader implications of ketamine therapy outside of clinical settings.
In other news, MDMA-assisted psychotherapy for PTSD faces setbacks after the FDA pulled approval, citing data manipulation and other ethical issues in its trials. But with 20 new trials on the horizon, this psychedelic therapy may yet have another shot.
Meanwhile, liquid formulations of ADHD and bipolar medications are making waves. We discuss Onyida, a newly approved liquid formulation of Clonidine XR, and the re-release of liquid lithium citrate, a long-missed option for elderly patients or those needing to taper slowly.
We also break down the new draft guidelines from the American Society of Addiction Medicine for tapering benzodiazepines. With tapering posing its own risks, the guidelines suggest a careful, patient-centric approach, especially for vulnerable populations like the elderly or pregnant women.
Next, we turn to a study from Denmark that offers some reassurance about the controversial use of antidepressants in bipolar disorder. While the study found no increased risk of manic episodes, its lack of randomization leaves important questions unanswered.
Finally, we bring updates on e-cigarettes and smoking cessation. A new trial shows that nicotine-containing e-cigarettes are as effective as Chantix for helping adults quit smoking, but the rise of flavored vape products continues to stir debate. At the same time, e-cigarettes themselves pose significant health risks, including nicotine addiction, lung damage, and heart problems.
And in exciting news for PTSD patients, Brexpiprazole, also known as Rexulti, shows promise as an add-on treatment to the SSRI sertraline, with two out of three clinical trials reporting significantly improved outcomes. But will the FDA approve it? We examine the risks and benefits of this new therapy.
We also touch on a new phase 3 trial for CBD oil, which offers a glimmer of hope for treating anxiety, though its high cost remains a barrier for most patients.
With so many developments, it’s a critical time for clinicians, patients, and researchers alike to stay informed. Join us as we break down these top nine stories and what they mean for the future of mental health care.
source
